Financial Disclosure: Dr Smoller has served as a consultant for Eli Lilly and Company; has received honoraria from Hoffmann-La Roche, Inc, Enterprise Analysis Corp, and MPM Capital;
and has served on an advisory board for Roche Diagnostics Corporation.
A patent application related to work described in this article is pending. Dr Paulus has been a paid consultant for GlaxoSmithKline Pharmaceuticals; has received research support from Forest Laboratories, GlaxoSmithKline, Roche, Sepracor, the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the VA Merit System; and has received speaking honoraria from Pfizer. Dr Biederman currently receives research support from Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceuticals Inc, McNeil, Otsuka, Shire, the NIMH, and the National Institute of Child Health and Human Development; is currently a consultant/advisory board member for Janssen, McNeil, Novartis, and Shire; and currently serves on the speakers bureaus of Janssen, McNeil, Novartis, Shire, and UCB Pharma, Inc.
In addition, he has received research support, consultation fees, or speaker's fees from Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Company, Esai, Forest, Gliatech, NARSAD, Neurosearch, New River, the NIDA, Novartis, Noven, Pfizer, Pharmacia, the Prechter Foundation, the Stanley Foundation, and Wyeth. Dr Rosenbaum has served on one or more advisory boards for AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly and Company, Forest, GlaxoSmithKline, Janssen, MedAvante, Novartis, Orexigen, Pfizer, Roche Diagnostics, Sanofi, Shire, Sepracor, Somerset, and Wyeth; has offered consultation to Compellis, EPIX, Neuronetics, Organon, Somaxon, and Supernus; and has received one or more honoraria for lectureship from Boehringer-Ingelheim, Bristol-Myers Squibb, Cyberonics, Eli Lilly and Company, Forest, and Schwartz. He also attended the Massachusetts General Hospital Psychiatry Academy, sponsored by AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly and Company, GlaxoSmithKline, Janssen, and Wyeth. He has equity holdings in Compellis, MedAvante, and Somaxon. Dr Stein has been a paid consultant for AstraZeneca, Avera Pharmaceuticals, BrainCells Inc, Bristol-Myers Squibb, Cephalon, Eli Lilly and Company, EPI-Q Inc, Forest Laboratories, GlaxoSmithKline Pharmaceuticals, Hoffmann-La Roche Pharmaceuticals, Integral Health Decisions Inc, Jazz Pharmaceuticals, Johnson & Johnson, Mindsite, Pfizer, Sanofi-Aventis, Solvay Pharmaceuticals, Transcept Pharmaceuticals Inc, UCB Pharma, Virtual Reality Medical Center, and Wyeth and has received research support from Eli Lilly and Company, Forest Laboratories, GlaxoSmithKline, and UCB Pharma.